| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 470 | 353 | +33.2% |
| EBITDA | 135 | 104 | +29.9% |
| EBITDA margin | 28.7% | 29.4% | −0.7 pts |
| Profit before tax | 84.0 | 71.4 | +17.6% |
| Net profit | 62.5 | 53.8 | +16.2% |
| EPS | ₹5.97 | ₹5.27 | +13.3% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 12,236 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 438 | 438 | 591 | 318 | 73.5 | ||
| 15.5 | 15.5 | 6.8 | 6.0 | 5.0 | ||
| 11,813 | — | — | — | — | ||
| 1,820 | 1,703 | 1,516 | 1,297 | 1,174 | ||
| — | +12.4% | +16.9% | +10.5% | — | ||
| 575 | 544 | 490 | 429 | 396 | ||
| 31.6% | 32.0% | 32.3% | 33.1% | 33.8% | ||
| 417 | 394 | 351 | 317 | 306 | ||
| 290 | 282 | 244 | 218 | 212 | ||
| 15.9% | 16.5% | 16.1% | 16.8% | 18.1% | ||
| ₹28.10 | ₹27.41 | ₹23.97 | ₹21.37 | ₹20.76 | ||
| — | +14.3% | +12.2% | +2.9% | — | ||
| — | 420 | 396 | 321 | 327 | ||
| — | −216 | −146 | −354 | −141 | ||
| 203 | 203 | 250 | −32.2 | 186 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 12,235.8 | |
| - Cash, Equiv & ST Investments | 73.5 | 317.6 | 591.0 | 438.4 | 438.4 | |
| + Minority Interest | 5.0 | 6.0 | 6.8 | 15.5 | 15.5 | |
| Enterprise Value | — | — | — | — | 11,813.0 | |
| Revenue | 1,173.6 | 1,296.9 | 1,515.9 | 1,703.1 | 1,820.1 | |
| Growth %, YoY | — | +10.5 | +16.9 | +12.4 | — | |
| EBITDA | 396.4 | 428.9 | 489.9 | 544.2 | 575.2 | |
| Margin % | 33.78 | 33.07 | 32.32 | 31.95 | 31.60 | |
| EBIT | 306.1 | 316.8 | 351.4 | 393.6 | 416.6 | |
| Net Income | 212.4 | 218.3 | 244.2 | 281.5 | 290.3 | |
| Margin % | 18.10 | 16.83 | 16.11 | 16.53 | 15.95 | |
| EPS, Adj (current shares) | 20.76 | 21.37 | 23.97 | 27.41 | 28.10 | |
| Growth %, YoY | — | +2.9 | +12.2 | +14.3 | — | |
| Cash from Operations | 327.2 | 321.4 | 395.7 | 419.7 | — | |
| Capital Expenditures | -141.3 | -353.6 | -145.7 | -216.5 | — | |
| Free Cash Flow | 185.9 | -32.2 | 250.0 | 203.2 | 203.2 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
Rainbow Childrens Medicare (NSE: RAINBOW) had a market capitalisation of ₹12,155 crore at the 29 October 2026 close (₹1,196.80 a share), a PE ratio of 42.6 on the last four quarters' profit and a price-to-book ratio of 7.38. In FY26 its consolidated net profit attributable to shareholders was ₹278 crore on revenue of ₹1,703 crore; in Q1 FY27 (April–June 2026) it was ₹60.6 crore, up 13.2% year on year. It had no borrowings on 31 March 2026. Promoters held 49.83% of the shares on 30 September 2026.
Rainbow Childrens Medicare's PE ratio is 42.6 at the 29 October 2026 close (₹1,196.80 a share): a market capitalisation of ₹12,155 crore divided by consolidated net profit attributable to shareholders of ₹285 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹278 crore) it is 43.7.
Rainbow Childrens Medicare's price-to-book (PB) ratio is 7.38 at the 29 October 2026 close: a market capitalisation of ₹12,155 crore divided by shareholders' equity (book value) of ₹1,648 crore on 31 March 2026. That is a book value of ₹162.27 per share against a share price of ₹1,196.80.
Rainbow Childrens Medicare's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,648 crore on 31 March 2026, up 12.3% from ₹1,468 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹12,155 crore at the 29 October 2026 close.
Rainbow Childrens Medicare's market capitalisation was ₹12,155 crore at the 29 October 2026 close: 10.16 crore shares at ₹1,196.80 each.
Yes. Rainbow Childrens Medicare had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹438 crore of cash, bank balances and current investments.
Rainbow Childrens Medicare's basic earnings per share (EPS) were ₹27.41 in FY26, against ₹23.97 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹28.11.
Rainbow Childrens Medicare's debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹1,664 crore. A year earlier, on 31 March 2025, it was 0.00.
Rainbow Childrens Medicare's book value per share was ₹162.27 on 31 March 2026: shareholders' equity of ₹1,648 crore divided by the 10.16 crore shares in issue, up 12.2% from ₹144.58 a year earlier. The share price at the 29 October 2026 close was ₹1,196.80.
Rainbow Childrens Medicare's dividend yield is 0.29% at the 29 October 2026 close: dividends of ₹3.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,196.80. They were ₹3.50 on 21 July 2026.
In FY26, Rainbow Childrens Medicare's return on equity (ROE) was 17.9% and its return on capital employed (ROCE) was 16.3%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 17.9% and ROCE 16.6%.
Promoters held 49.83% of Rainbow Childrens Medicare on 30 September 2026, down 0.01 percentage points from 49.84% the previous quarter and down 0.02 percentage points from 49.85% a year earlier, according to the shareholding pattern filed with NSE.
On 30 September 2026, Rainbow Childrens Medicare's shares were held by promoters 49.83%, foreign portfolio investors (FII/FPI) 14.66%, domestic institutions (DII) 23.28% (including mutual funds at 18.84%) and retail and other non-institutional investors 11.83%. Over the year, FII holding was down 7.19 percentage points from 21.85% and DII holding was up 5.82 percentage points from 17.46%.
In 2026, Rainbow Childrens Medicare has declared one dividend: ₹3.50 with record date 21 July 2026.
In FY26, Rainbow Childrens Medicare generated ₹420 crore of cash from operations and spent ₹216 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹203 crore. In FY25 it was ₹250 crore.
Rainbow Childrens Medicare will announce its Q2 FY27 results (July–September 2026) on Saturday, 31 October 2026, the date of the board meeting it has notified to the exchanges.
Rainbow Childrens Medicare's latest results are for Q1 FY27 (April–June 2026), filed on 30 July 2026: consolidated net profit attributable to shareholders ₹60.6 crore, up 13.2% from ₹53.5 crore in Q1 FY26; revenue from operations ₹470 crore, up 33.2% year on year.
In FY26 (April 2025–March 2026), Rainbow Childrens Medicare's consolidated net profit attributable to shareholders was ₹278 crore, up 14.3% from ₹243 crore in FY25, on revenue from operations of ₹1,703 crore (up 12.4%). Over three years, from FY23, net profit was up 32.0%.
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Rainbow Childrens Medicare's PE ratio is 43.7, the lowest of the four: Apollo Hospitals Enterprise 60.7, Fortis Healthcare 54.7 and Krishna Institute of Medical Sciences 122.2, a peer average of 79.2. Each is the company's market capitalisation at that price divided by its FY26 net profit.
On FY26 consolidated figures, against Apollo Hospitals Enterprise, Fortis Healthcare and Krishna Institute of Medical Sciences: Rainbow Childrens Medicare's operating margin of 23.1% is the highest of the four (Apollo Hospitals Enterprise 11.5%, Fortis Healthcare 17.9%, Krishna Institute of Medical Sciences 13.3%; peer average 14.2%); its return on equity of 17.9% is the second highest of the four (Apollo Hospitals Enterprise 22.0%, Fortis Healthcare 11.1%, Krishna Institute of Medical Sciences 11.0%; peer average 14.7%); its revenue growth over three years of 13.2% a year is the third highest of the four (Apollo Hospitals Enterprise 14.9% a year, Fortis Healthcare 13.2% a year, Krishna Institute of Medical Sciences 21.1% a year; peer average 16.4% a year).
In FY26, Rainbow Childrens Medicare earned net profit attributable to shareholders of ₹278 crore on revenue of ₹1,703 crore, against ₹1,942 crore on ₹25,229 crore for Apollo Hospitals Enterprise. Rainbow Childrens Medicare's operating margin was 23.1% (Apollo Hospitals Enterprise 11.5%) and its return on equity 17.9% (Apollo Hospitals Enterprise 22.0%). At the 29 October 2026 close, Rainbow Childrens Medicare's market capitalisation was ₹12,155 crore against ₹1,17,916 crore for Apollo Hospitals Enterprise, and its PE ratio on FY26 profit 43.7 against 60.7.
From Rainbow Childrens Medicare's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.